Oregon Health & Science University is part of the randomized, double-blind Phase 3 trial that is evaluating the experimental drug aficamten, which was developed by Cytokinetics to treat the ...

Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. If all goes well, it could be approved by September 2025. Aficamten had favorable Phase 3 data, so it could have ...

Gilead legal chief, leaves Cytokinetics after 7 months as CLO. His exit comes as the biotech awaits FDA decision on a heart ...

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to ...

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics’ near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...

Cytokinetics' lead asset, Aficamten, shows promise in treating obstructive hypertrophic cardiomyopathy (oHCM) with significant improvements in exercise capacity and fewer adverse events compared ...

Cytokinetics (CYTK) on Monday shared new analyses related to aficamten’s effects associated with standard of care combination therapy and its long-term effects on cardiac structure and function ...

Longer-term treatment with aficamten resulted in statistically significant improvements (mean ±SD) in measures of cardiac structure and function including left ventricular mass index (-9.8 g/m2 ...

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics’ near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...